Quantcast
Last updated on April 17, 2014 at 13:47 EDT

Latest Mitemcinal Stories

2013-05-20 08:27:43

BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that RM-131 significantly accelerates early gastric emptying and reduces upper gastrointestinal (GI) symptoms in type 1 diabetic patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2013 conference in...

2013-04-16 08:28:12

BOSTON, April 16, 2013 /PRNewswire/ -- Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility. "This is the first of two studies we plan to initiate this year to assess the efficacy and safety of RM-131 for the treatment of lower GI functional disorders," said Elizabeth Stoner, MD,...

2012-06-06 06:26:33

BOSTON, June 6, 2012 /PRNewswire/ -- Rhythm announced today the initiation of a Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of gastroparesis in patients with Type I and Type II diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastric motility. "We are excited about the clinical profile of RM-131 as we bring it forward into Phase 2 development," said Liz Stoner, MD, Chief Development Officer of Rhythm. "Extensive...

2012-05-22 06:25:26

BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego. The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose crossover...

2008-06-17 06:00:07

Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development. It is a potent prokinetic agent initially being developed for the treatment of mild-to-moderate gastroparesis. The Phase I study showed that TZP-102 has excellent oral bioavailability in man and is safe and...